MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

Search

Amgen Inc

Chiusa

SettoreSettore sanitario

279.51 -3.36

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

277.46

Massimo

293.51

Metriche Chiave

By Trading Economics

Entrata

-2.2B

627M

Vendite

586M

9.1B

P/E

Media del settore

38.889

61.151

EPS

5.31

Rendimento da dividendi

3.23

Margine di Profitto

6.901

Dipendenti

28,000

EBITDA

-517M

2.9B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+13.02% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.23%

2.71%

Utili prossimi

1 mag 2025

Prossima data del Dividendo

6 giu 2025

Prossima data del' Ex Dividendo

16 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

5B

158B

Apertura precedente

282.87

Chiusura precedente

279.51

Notizie sul Sentiment di mercato

By Acuity

33%

67%

87 / 385 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Amgen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 feb 2025, 21:29 UTC

Utili

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30 ott 2024, 20:18 UTC

Utili

Amgen Posts Higher 3Q Sales on Strong Demand

28 feb 2025, 12:00 UTC

Notizie principali

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 21:02 UTC

Utili

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen 4Q Adj EPS $5.31 >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen 4Q Rev $9.1B >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen 4Q EPS $1.16 >AMGN

4 feb 2025, 21:01 UTC

Utili

Amgen 4Q Net $627M >AMGN

28 gen 2025, 10:30 UTC

Notizie principali

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27 dic 2024, 07:00 UTC

Utili

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23 dic 2024, 15:04 UTC

Notizie principali

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dic 2024, 14:53 UTC

Notizie principali

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30 nov 2024, 12:00 UTC

Notizie principali

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26 nov 2024, 12:34 UTC

Notizie principali

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4 nov 2024, 12:00 UTC

Notizie principali

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30 ott 2024, 20:02 UTC

Utili

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30 ott 2024, 20:02 UTC

Utili

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30 ott 2024, 20:02 UTC

Utili

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30 ott 2024, 20:02 UTC

Utili

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 ott 2024, 20:02 UTC

Utili

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30 ott 2024, 20:01 UTC

Utili

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30 ott 2024, 20:01 UTC

Utili

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 ott 2024, 20:01 UTC

Utili

Amgen 3Q Worldwide Neulasta Sales $110M >AMGN

Confronto tra pari

Modifica del prezzo

Amgen Inc Previsione

Obiettivo di Prezzo

By TipRanks

13.02% in crescita

Previsioni per 12 mesi

Media 332.71 USD  13.02%

Alto 389 USD

Basso 280 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amgen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

18 ratings

11

Acquista

6

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 306.86Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

87 / 385 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.